Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0001419

Quetiapine for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Quetiapine hemifumarate salt, 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol hemifumarate, Quetiapine fumarate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C21H25N3O2S · 0.5C4H4O4
Numéro CAS:
111974-72-2
Poids moléculaire :
441.54
Numéro MDL:
MFCD03423782
Code UNSPSC :
41116107
ID de substance PubChem :
329831415
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

quetiapine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

OC(=O)\C=C\C(O)=O.OCCOCCN1CCN(CC1)C2=Nc3ccccc3Sc4ccccc24.OCCOCCN5CCN(CC5)C6=Nc7ccccc7Sc8ccccc68

InChI

1S/2C21H25N3O2S.C4H4O4/c2*25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21;5-3(6)1-2-4(7)8/h2*1-8,25H,9-16H2;1-2H,(H,5,6)(H,7,8)/b;;2-1+

Clé InChI

ZTHJULTYCAQOIJ-WXXKFALUSA-N

Informations sur le gène

human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Quetiapine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Quetiapine hemifumarate is an atypical antipsychotic, a combined serotonin (5HT2) and dopamine (D2) receptor antagonist.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0001657

Quetiapine fumarate, European Pharmacopoeia (EP) Reference Standard

1592704

Quetiapine fumarate, United States Pharmacopeia (USP) Reference Standard, monograph mol wt. 883.09 ((C21H25N3O2S)2 · C4H4O4)

1592715

Quetiapine System Suitability, United States Pharmacopeia (USP) Reference Standard

1592781

Quetiapine Related Compound G, United States Pharmacopeia (USP) Reference Standard

1592737

Quetiapine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1592792

Quetiapine Related Compound H, United States Pharmacopeia (USP) Reference Standard

PHR1856

Quetiapine Fumarate, Pharmaceutical Secondary Standard; Certified Reference Material

PHR3121

Quetiapine Related Compound B, pharmaceutical secondary standard, certified reference material

PHR3122

Quetiapine Related Compound G, pharmaceutical secondary standard, certified reference material

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Andre Tapp et al.
Drug and alcohol dependence, 149, 18-24 (2015-02-16)
Cocaine addiction continues to be a significant healthcare issue, yet there are no FDA approved medications for the treatment of cocaine use disorder within the United States. This 12-week, prospective, double-blind, randomized, placebo-controlled study examined the effectiveness of quetiapine (Seroquel
Miho Shishikura et al.
Bioscience trends, 8(3), 149-154 (2014-07-18)
It is of importance to determine whether antipsychotic drugs currently prescribed for schizophrenia exert D-amino acid oxidase (DAO)-inhibitory effects. We first investigated whether human (h)DAO can metabolize D-kynurenine (D-KYN) to produce the fluorescent compound kynurenic acid (KYNA) by using high-performance
Piotr Kulinowski et al.
International journal of pharmaceutics, 484(1-2), 235-245 (2015-02-24)
Motivation for the study was the lack of dedicated and effective research and development (R&D) in vitro methods for oral, generic, modified release formulations. The purpose of the research was to assess multimodal in vitro methodology for further bioequivalence study
Susanna Waters et al.
Journal of neural transmission (Vienna, Austria : 1996), 121(11), 1337-1347 (2014-05-13)
The dopaminergic stabilizers pridopidine [4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine] and ordopidine [1-ethyl-4-(2-fluoro-3-(methylsulfonyl)phenyl)piperidine] inhibit psychostimulant-induced hyperactivity, and stimulate behaviour in states of hypoactivity. While both compounds act as dopamine D2 receptor antagonists in vitro, albeit with low affinity, their specific state-dependent behavioural effect profile is

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique